However, given the evidence that a positive 18F-FTP tau PET result (as rated by FDA-approved visual read criteria) reliably detects primarily advanced stages of tau pathology (Braak stages V–VI), a negative FTP tau PET visual read does not exclude the presence of clinically meaningful tau pathology (i.e., Braak stages III–IV), which represents the median tau pathology seen at autopsy in patients who died with MCI, as well as in some patients who died with dementia (161). The gene discussed is MAPT; the disease is dementia.